Tarnished HALO For Targacept/AstraZeneca Nicotinic Receptor Modulator
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Targacept and AstraZeneca halted further development of their neuronal nicotinic receptor modulator AZD3480 for cognitive dysfunction in schizophrenia after the drug failed to meet its primary endpoint in the Phase II HALO trial, but a final decision on the compound will wait for an ongoing trial in attention-deficit/hyperactivity disorder
You may also be interested in...
Roche Snaps Up Memory, Gains CNS Drugs
Swiss drugmaker gains partnered compounds in Alzheimer’s and schizophrenia via $50 million deal.
AstraZeneca R&D: Aim Early To Cut Cycle Time, Build Phase II Pipeline
Current R&D strategy emphasizes improvements to R&D processes, like trying to reduce costs and cycle time. Making go/no-go decisions earlier on is also a goal, R&D execs say in an interview. The firm is in a building phase as it makes up for some major Phase III failures in recent years. AstraZeneca's current late-stage pipeline is mostly focused on lifecycle management
Genzyme Receives Complete Response, Warning Letters For Lumizyme
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter